
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics is poised for success with the positive Phase 1b PIONEER trial results for their lead product candidate, Pociredir, which has shown significant improvements in hemoglobin level and markers of anemia and hemolysis in patients with sickle cell disease. The company's strong cash position and diversified pipeline, including programs targeting rare aplastic anemias, provide potential for long-term growth. The upcoming release of the full PIONEER dataset in 1Q26 and the potential for direct transition to a registrational trial, along with data from upcoming studies in other diseases, could further support the company's market capture and solidify their position as a best-in-class HbF modulator.
Bears say
Fulcrum Therapeutics is facing several challenges with their primary drug candidate, Pociredir, as it is currently being evaluated for sickle cell disease (SCD) treatment. There are concerns about the drug's effectiveness and sustainability, as well as the potential for competition in the oral therapy landscape. Additionally, there are uncertainties surrounding the optimal dose for the drug and any potential adverse effects. The company also faces financial risks, such as the need for additional capital and potential dilution of stock.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares